Conference Coverage
about 1 month ago
Retina World Congress 2026: The dopamine-AMD connectionabout 1 month ago
MacTel masquerades: How to spot what others missabout 2 months ago
Retina World Congress 2026: EYP-1901 phase 2 updates for wet AMD and DMETrending on the Eye Care Network
1
FDA grants RMAT designation to Emmecell's EO2002 for corneal endothelial disease
2
Opus Genetics reaches FDA alignment on phase 3 registrational design for OPGx-LCA5 gene therapy
3
NeuroOp Guru: What a big data study reveals about NAION and stroke risk
4
Port Delivery System Therapies in Retinal Vascular Diseases
5
Polyendocrine metabolic ovarian syndrome: looking past the reproductive system to the eye
Latest News
Jul 06, 2026 | Publication
Redefining the possible: MCO-010’s 3-year retinal data
Could FLIO predict how fast geographic atrophy will grow?
Jul 04, 2026
Vaccinated patients show markedly lower risk of new-onset idiopathic uveitis
Jul 03, 2026
Detecting peripheral retinal lesions in children with myopia
Jul 01, 2026
Optimizing anti-VEGF in AMD, DME, and RVO: Strategies for durable disease control
Jun 30, 2026
Advertisement
Shorts
0:56
Communicating with patients about Encelto with Dr. Wykoff
3 days ago
1:02
Anti-VEGF in RVO with Katherine Talcott, MD
18 days ago
0:50
RVO risk factors and systemic outcomes
20 days ago
1:04
SOL-1 superiority trial explained with Mark Barakat, MD
22 days ago
0:23
The Trials Reshaping Retina Care With Arshad M. Khanani, MD, MA, FASRS
a month ago
0:25
Why Ergonomics Matters More Than Most Surgeons Realize
2 months ago
0:24
Why Retina Specialists Should Care About Facial Fillers
2 months ago
1:05
Jennifer Murdock, MD, on What 'Ozempic Face' Really Means
2 months ago
1:13
Why Every Stage of Your Career Is A Chance to Mentor Someone | Eichenbaum Acorns
2 months ago
1:23
Women in Surgical Retina | Eichenbaum Acorns
2 months ago
Digital Edition
Modern Retina
How this gene-agnostic optogenetic approach could fill a critical gap for advanced inherited retinal degeneration.
Modern Retina
Ultra-widefield imaging reveals early retinal risk in pediatric patients.
Modern Retina
SOL-1 results show intravitreal axitinib hydrogel delivered superior vision
maintenance and anatomic outcomes through 52 weeks.
Modern Retina
New pathways are reshaping the management of retinal disease.
Modern Retina
Imaging and biomarkers are driving earlier, more individualized GA treatment
Modern Retina
When no retina podcast was available, Jayanth Sridhar, MD, created one—and learned lessons about branding, bandwidth, and mentorship along the way.
Modern Retina
A trio of retina specialists recently reviewed the clinical benefits of aflibercept 8 mg, including its extended dosing intervals, improved patient satisfaction, and enhanced treatment outcomes for various conditions.
Modern Retina
Explore early MacTel diagnosis with OCT/FA, who qualifies for Encelto implant, and how costs, reimbursement, and surgery shape timely retina care.
Modern Retina
For Jordan M. Graff, MD, FACS, early adoption is about reigniting the thrill of discovery and navigating the rewards, risks, and realities of translating innovation into practice.
Podcasts
Continuing Medical Education
Advertisement
All News
Advertisement
SOL-1 results show intravitreal axitinib hydrogel delivered superior vision maintenance and anatomic outcomes through 52 weeks.
New IGF-1R antibody Lumvoa receives FDA nod for active and chronic thyroid eye disease, offering rapid proptosis relief and diplopia improvement.
A randomized trial found that 8 weeks of daily use of the Calm Health app significantly improved mental health outcomes in adults with non-infectious uveitis.
A prospective pilot study finds focal photopic microperimetry may detect cone-mediated losses that lesion size and visual acuity do not reflect.
Retina cells that sense light falter in Alzheimer’s, potentially derailing sleep and body clocks—pointing to new diagnostic and treatment angles.
StemSight secures new patents for scalable induced pluripotent stem cells-derived limbal stem cells, boosting STE-101’s path to off-the-shelf limbal stem cell deficiency therapy and upcoming Series A.
Learn how FDA’s interchangeable ranibizumab biosimilar may streamline injections, cut costs, and guide safe switching for retina patients.
A retrospective study identifies thin choroid as the key factor behind ungradable ultrawidefield green-light fundus autofluorescence images in geographic atrophy.
Alkeus Pharmaceuticals has dosed the first participant in the phase 3 NORTHSTAR trial of oral gildeuretinol for Stargardt disease, a condition with no approved treatments.
Guidance includes building on existing science, reducing redundant testing, and accelerating treatments for rare and life-threatening diseases
Advertisement
FDA approves ranibizumab-hkdz as first interchangeable biosimilar ranibizumab available in both vials and prefilled syringes
Published: | Updated:
The FDA has approved ranibizumab-hkdz (Ranluspec; Lupin Limited) as an interchangeable biosimilar for wet AMD, DME, DR, RVO, and mCNV.
A propensity-matched retrospective analysis of more than 920,000 adults finds a 30% higher risk of incident uveitis following human papillomavirus infection.
Researchers report pseudophakic patients implanted with a peripheral vision IOL detected roadway hazards significantly faster than those receiving a standard monofocal lens.
Therini Bio begins a phase 1b DME trial of THN391, an intravitreal antibody targeting fibrin-driven retinal inflammation.
Genetic testing transforms inherited eye disease care, but expert interpretation matters—learn why false negatives and new gene therapies reshape retina practice.
Advertisement
Advertisement